Related references
Note: Only part of the references are listed.
Article
Medical Laboratory Technology
Orianne Wagner-Ballon et al.
Summary: This multicenter study demonstrates the robustness of the monocyte assay in distinguishing chronic myelomonocytic leukemia from other causes of monocytosis. It also confirms the possibility of using this assay in bone marrow samples.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Qi Gao et al.
Summary: A single tube flow cytometry assay was developed for monitoring the treatment response of B-ALL minimal/measurable residual disease. The method showed good sensitivity and accuracy, allowing for disease detection independent of CD19 and CD22 expression.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Fan-Chi Hsu et al.
Summary: Detection of measurable residual disease (MRD) using flow cytometry after chemotherapy is a standard measure of early response in acute myeloid leukemia (AML) patients. Myeloid leukemia associated with Down Syndrome (ML-DS) is a unique form of AML. Understanding the differences in hematopoiesis between patients with or without DS is important for accurately identifying residual leukemia in ML-DS patients.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Review
Medical Laboratory Technology
Qi Gao et al.
Summary: Flow cytometry is essential in the diagnosis and monitoring of B cell lymphoma and plasma cell neoplasms. However, the use of conventional gating strategies to isolate neoplastic B or plasma cells is becoming challenging due to the increasing number of antibody therapeutics targeting B/plasma cell-lineage markers. This review summarizes the current targeted therapies used in B and plasma cell neoplasms and proposes alternative approaches to overcome analysis challenges.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Sara L. Huang et al.
Summary: This study investigates the mechanism and diagnostic significance of sIg negative mature B cells. It found that sIg negative reactive B cells were polytypic, while sIg negative mature B-cell lymphomas showed distinct patterns of abnormal light chain expression. Therefore, a diagnosis of B-cell lymphoma should not be based solely on the lack of sIg, and further evaluation of cIg expression is necessary.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Review
Medical Laboratory Technology
Xueyan Chen et al.
Summary: Minimal/measurable residual disease (MRD) is the most important independent prognostic factor in B-lymphoblastic leukemia (B-LL) patients. MRD monitoring has significantly improved outcomes for pediatric and adult patients. However, the impact of targeted immunotherapy on immunophenotype poses challenges for MRD detection using standard gating strategies, leading to the development of novel flow cytometric approaches for post-targeted therapy MRD monitoring.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Review
Medical Laboratory Technology
Daniel S. Martig et al.
Summary: Hodgkin-like lymphomas, including classic Hodgkin lymphoma and other subtypes, are pathobiologically related with similar morphologic growth patterns. Over the past 15 years, antibody-fluorochrome combinations have been developed to accurately distinguish these entities, with diagnostic algorithms based on the characterization of background B-cell and T-cell populations. This review summarizes morphologic and immunophenotypic features, as well as flow cytometric insights, of neoplastic and reactive populations in this unique subset of lymphomas.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Kah Teong Soh et al.
Summary: The study designed and evaluated a consensus protocol to reduce inter-laboratory variation in multiple myeloma measurable residual disease (MRD) analysis. Results showed improved consistency in MRD- status and near-unanimous agreement on sample adequacy by adopting the consensus method.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Nupur Das et al.
Summary: This study evaluated the immunophenotypic profile and post-therapy alteration in antigenic expression of normal, reactive, and aberrant plasma cells in multiple myeloma, and its impact on measurable residual disease assessment. The results showed that polyclonal plasma cells exhibited aberrant antigen expression, which was more frequent in post-therapy samples. Immunomodulation was observed in post-therapy samples, with changes in antigen expression in a significant proportion of samples. These findings emphasize the importance of validating MRD testing under normal and reactive conditions.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Kevin E. Shopsowitz et al.
Summary: In this study, optimized radar plots were developed for B-ALL MRD analysis, which successfully distinguished diverse B-lymphoblast populations and non-malignant CD19-positive populations. The optimized radar plots outperformed PCA plots and showed comparable performance to UMAP, with better generalizability to new data. This novel optimization strategy for radar plots could be applied to other MRD panels and clinical scenarios.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Ya-Zhe Wang et al.
Summary: ZNF384 rearrangement has been identified as a new subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Comprehensive immunophenotypic studies showed that patients with ZNF384 rearrangement have distinct features compared to other BCP-ALL subtypes. A flow cytometry scoring system including CD10%, CD33MFI, CD13%, and CD123MFI was proposed and verified to predict ZNF384 rearrangement with high sensitivity and specificity.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Ekaterina Mikhailova et al.
Summary: The addition of CD22, CD24, and iCD79a with CD10 allows for the identification of B-lineage compartment including residual tumor blasts in virtually all patients with BCP-ALL after CD19-directed treatment for MFC-MRD searching.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Annabel McMillan et al.
Summary: The study successfully adopted a multicolor flow cytometry (MCF) method for MM MRD detection, which can be stably delayed for up to 6 days, providing the possibility for wider use in smaller laboratories. The real-world study found that 17% of patients achieved MRD negativity after UK standard induction therapy.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Ting Zhou et al.
Summary: The study identified two CD22-positive non-neoplastic cell populations in peripheral blood, including a progenitor population of uncertain lineage and a mature B-cell population, mimicking B-ALL. These populations were detected in a significant percentage of B-ALL patients and had distinct antigen expression patterns, making them reliably distinguishable from B-ALL.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Letter
Medical Laboratory Technology
Thulasi Raman Ramalingam et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Article
Medical Laboratory Technology
Harshini Sriram et al.
Summary: This study investigated the expression pattern of BCMA in abnormal plasma cells of multiple myeloma (MM) patients from India. The findings showed that BCMA is highly expressed in a majority of MM patients, both at diagnosis and relapse. This suggests that BCMA could be an important target for therapy in Indian MM patients.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2022)
Letter
Medical Laboratory Technology
Andrea Espasa et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2021)
Article
Medical Laboratory Technology
Ru Feng et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2018)
